Contrasting LENSAR (NASDAQ:LNSR) and Adagio Medical (NASDAQ:ADGM)

LENSAR (NASDAQ:LNSR) and Adagio Medical (NASDAQ:ADGM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Profitability

This table compares LENSAR and Adagio Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LENSAR	-34.03%	-49.02%	-21.12%
Adagio Medical	N/A	160.59%	40.99%

Analyst Ratings

This is a summary of current ratings and target prices for LENSAR and Adagio Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	0	2	0	0	2.00
Adagio Medical	0	0	0	0	0.00

LENSAR presently has a consensus price target of $15.00, indicating a potential upside of 6.69%. Given LENSAR’s stronger consensus rating and higher probable upside, equities analysts clearly believe LENSAR is more favorable than Adagio Medical.

Volatility & Risk

LENSAR has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Adagio Medical has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500.

Earnings & Valuation

This table compares LENSAR and Adagio Medical”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$53.49 million	3.10	-$14.38 million	($2.72)	-5.17
Adagio Medical	$266,000.00	48.57	-$2.13 million	N/A	N/A

Adagio Medical has lower revenue, but higher earnings than LENSAR.

Institutional and Insider Ownership

40.2% of LENSAR shares are held by institutional investors. Comparatively, 48.1% of Adagio Medical shares are held by institutional investors. 38.5% of LENSAR shares are held by insiders. Comparatively, 53.5% of Adagio Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Adagio Medical beats LENSAR on 7 of the 11 factors compared between the two stocks.

About LENSAR

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

About Adagio Medical

Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. The company is based in Laguna Hills, California.